BioSight
Therapeutics for Oncology and Hematological Disorders
Company Overview
Snapshot
Founded in November 1999 by Stela Gengrinovitch, PhD and Mark Gengrinovitch, BioSight operated with 1–10 employees. The company raised $62.5M across 5 funding rounds from 9 investors. BioSight was acquired by Ayala Pharmaceuticals in October 2023.
Business overview
BioSight was a phase-2 clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. The company investigated BST-236 as a single agent in a phase-2b trial for first-line treatment of acute myeloid leukemia (AML), following a successful phase-1/2a trial. BioSight operated within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the Pharmaceuticals market.
Strategic signal
In October 2023, BioSight was acquired by Ayala Pharmaceuticals, marking a significant exit for the biotechnology firm. This acquisition signals a consolidation within the oncology therapeutics market and indicates the strategic value placed on BioSight's clinical-stage assets, particularly its lead product BST-236, by larger pharmaceutical entities.
Log in to access full profile ›Company Intelligence Q&A
- What was BioSight's most significant corporate event?
- BioSight was acquired by Ayala Pharmaceuticals in October 2023, leading to its inactive status.
- What is BioSight's primary therapeutic focus?
- BioSight focused on developing therapeutics for hematological malignancies and disorders, with its lead product, BST-236, targeting acute myeloid leukemia (AML).
- When did BioSight secure its last disclosed funding round?
- In December 2020, BioSight closed a Series C financing round. Investors included Israel Biotech Fund and Arkin Bio.
- Did BioSight receive any special designations for its lead product?
- In August 2020, BioSight was granted U.S. FDA Fast Track Designation for BST-236 for the treatment of acute myeloid leukemia. Additionally, in June 2019, BioSight received Orphan Drug Designation from the FDA for BST-236 for the same indication.
- What was the status of BioSight's clinical trials for BST-236?
- In November 2022, BioSight launched a Phase 1/2 clinical trial of Aspacytarabine (BST-236) in combination with Venetoclax for first-line AML induction therapy, followed by Aspacytarabine consolidation.